RxDoctor Payments Data

Luz Vazquez, MD

Neurology · Port St Lucie, FLNPI 1568418325

Payments from drug & device makers

$7,905in general payments, 2019–2025

Across 315 payments — averaging $25.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • EMD Serono, Inc.$893
  • Neurocrine Biosciences, Inc.$468
  • AstraZeneca$389
  • Eisai Inc.$372
  • Livanova USA, Inc.$372
  • plus $4K from 35 others

What the payments were for

  • Speaking & faculty fees$220%
  • Food & beverage$7,72798%
  • Education$1552%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,905 in reported general payments places this provider in the 60th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$95,523
Medicare patients
192
Services billed
709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab19$181,842
Nurtec OdtRimegepant Sulfate37$60,745
BotoxOnabotulinumtoxina18$28,824
UbrelvyUbrogepant15$15,262
Pregabalin99$5,542
Memantine Hcl ErMemantine Hcl79$5,406
Lacosamide15$5,318
Gabapentin144$3,738
Levetiracetam74$3,065
Carbamazepine ErCarbamazepine24$2,941
Memantine Hcl107$2,845
Duloxetine Hcl41$2,518
Divalproex Sodium12$1,871
Donepezil Hcl99$1,853
Oxcarbazepine15$1,761

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$306$60,74537 claims
AbbVieBotox, Ubrelvy$1,320$44,08633 claims
Almatica Pharma LLCSertraline Hcl$24$12824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,434 neurology providers in Florida.

Other neurology in Port St Lucie

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →